

United States Patent [19]

Seelich

[11] Patent Number: 4,816,251

[45] Date of Patent: Mar. 28, 1989

[54] METHOD OF INACTIVATING
REPRODUCTIVE FILTERABLE
PATHOGENS IN FIBRINOGEN AND
FACTOR XIII COMPOSITIONS

[75] Inventor: Thomas Seelich, Vienna, Austria

[73] Assignee: Immuno Aktiengesellschaft fur
chemisch-medizinische Produkte,
Vienna, Austria

[21] Appl. No.: 775,609

[22] Filed: Sep. 13, 1985

[30] Foreign Application Priority Data

Sep. 28, 1984 [AT] Austria 3084/84

[51] Int. Cl.⁴ A61K 35/14

[52] U.S. Cl. 424/101; 514/2;
514/8; 530/381; 530/382

[58] Field of Search 435/236; 424/101;
530/382, 383; 514/2, 8

[56] References Cited

U.S. PATENT DOCUMENTS

4,297,344 10/1981 Schwinn et al. 530/383 X
4,362,567 12/1982 Schwarz et al. 424/101 X
4,414,976 11/1983 Schwartz et al. 128/334 R
4,456,590 6/1984 Rubinstein 424/101
4,640,834 2/1987 Eibl et al. 435/236 X

FOREIGN PATENT DOCUMENTS

142059 5/1985 European Pat. Off. .
WO82/03871 11/1982 PCT Int'l Appl. .
0103196 3/1984 United Kingdom .

OTHER PUBLICATIONS

The Merck Index, 10th Ed., #7240.

Biochem. Biophys. Res. Comm. 56, 793-798, 1974; L. L.

Shen et al.; "Fibrin Gel Structure; Influence of Calcium and Covalent Crosslinking on the . . ."

T. Seelich, H. Redl; "Theoretische Grundlagen des Fibrinklebers" and R. K. Schattauer Verlag, Stuttgart-N.Y., 199-208, 1980; K. Schimpf: Fibrinogen, Fibrin und Fibrinkleber.

Biomed. Res. 4, 155-160, 1983, S. Kasai, T. Kunimoto, K. Nitta—"Cross-Linking of Fibrin by Activated Factor XIII Stimulates Attachment, . . .".

"MIR" Publishers, Moscow 1969, pp. 471-475; Rosenberg et al.—XII, International Congress on Blood Transfusion, Abstracts, USP XVI, p. 298—Fibrinogen.

Fresenius' Z. Anal. Chem. 314: pp. 567-571, E. Scholz—"Karl Fischer Reagents Without Pyridine (8), Coulometric Determination of Water".

J. Bio. Chem. 244: pp. 4406-4412, 1969, K. Weber et al.—"The Reliability of Molecular Weight Determinations by Dodecylsulfate-Polyacrylamide Gel . . .".

Amer. J. Hyg., vol. 27: pp. 493-497, 1938, J. L. Reed et al., "A Simple Method of Estimating Fifty Per Cent Endpoints".

Primary Examiner—Sam Rosen

Attorney, Agent, or Firm—Burns, Doane, Swecker & Mathis

[57] ABSTRACT

There is disclosed a method of inactivating reproductive filterable pathogens in tissue adhesives containing fibrinogen and Factor XIII, with their biologic activity being largely preserved. In order to provide a tissue adhesive preparation of human or animal origin, which exhibits a high safety with respect to reproductive filterable pathogens and whose biologic activity is largely preserved, preparations having a minimum content of 100 units of Factor XIII/g of fibrinogen are heated in the dry state in the presence of an oxygen-free inert protective gas or under vacuum.

13 Claims, No Drawings